Oncology News and Research

RSS
Chimerix reports positive results from CMX157 Phase 1 clinical trial for HIV

Chimerix reports positive results from CMX157 Phase 1 clinical trial for HIV

UCSF physicians evlaute devices that could reduce hair loss in breast cancer patients undergoing chemotherapy

UCSF physicians evlaute devices that could reduce hair loss in breast cancer patients undergoing chemotherapy

Lilly suspends tasisulam global Phase III study in metastatic melanoma

Lilly suspends tasisulam global Phase III study in metastatic melanoma

TRL, Anaphore partner to develop novel protein therapies for autoimmune diseases

TRL, Anaphore partner to develop novel protein therapies for autoimmune diseases

Cedarlane to distribute TGR's new ELISA-One technology assay reagents in Canada and the US

Cedarlane to distribute TGR's new ELISA-One technology assay reagents in Canada and the US

PLATO Foundation launches first medical education activity during 33rd CTRC - AACR Symposium

PLATO Foundation launches first medical education activity during 33rd CTRC - AACR Symposium

Enzo Biochem first quarter total revenues increase 2% to $25.7 million

Enzo Biochem first quarter total revenues increase 2% to $25.7 million

Silicon Biosystems' newly formed subsidiary to commercialize DEPArray technology platform

Silicon Biosystems' newly formed subsidiary to commercialize DEPArray technology platform

bioTheranostics reports new findings from study evaluating Breast Cancer Index molecular oncology test

bioTheranostics reports new findings from study evaluating Breast Cancer Index molecular oncology test

Infinity extends global strategic alliance with Mundipharma for development, commercialization of IPI-926

Infinity extends global strategic alliance with Mundipharma for development, commercialization of IPI-926

Scientists create functioning human intestinal tissue from pluripotent stem cells

Scientists create functioning human intestinal tissue from pluripotent stem cells

Syndax reports promising results from entinostat preclinical studies in breast cancer

Syndax reports promising results from entinostat preclinical studies in breast cancer

Presence of circulating tumor cells in early-stage breast cancer doubles risk of relapse and death

Presence of circulating tumor cells in early-stage breast cancer doubles risk of relapse and death

Xeloda may reduce recurrence of faster growing breast cancers: Study

Xeloda may reduce recurrence of faster growing breast cancers: Study

Cancer researchers identify six gene markers in early stage NSCLC

Cancer researchers identify six gene markers in early stage NSCLC

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Boehringer Ingelheim reports positive results from afatinib phase IIb/III LUX-Lung 1 trial in advanced NSCLC

Combination therapy improves tumor response in HER2-positive breast cancer patients

Combination therapy improves tumor response in HER2-positive breast cancer patients

Prostate cancer study identifies 295 genes associated with clinical recurrence following radical prostatectomy

Prostate cancer study identifies 295 genes associated with clinical recurrence following radical prostatectomy

Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial

Novelos NOV-002 demonstrates positive results in Phase 2 neoadjuvant breast cancer trial

Study shows stereotactic radiation therapy as effective as surgery in elderly patients with early-stage lung cancer

Study shows stereotactic radiation therapy as effective as surgery in elderly patients with early-stage lung cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.